Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on June 23, 2017, with the report date of June 27, 2017. The filing discloses the entry into a material definitive agreement involving a new financing instrument.
Key Financial Metrics and Debt
- New Debt Facility: Executed a convertible future advance promissory note (the "Bridge Note") with a principal capacity of up to $1,000,000.
- Outstanding Balance: As of June 27, 2017, $590,000 is outstanding under this specific note.
- Interest Rate: Prime Rate (as published in the Wall Street Journal on the last day of each month) plus 1%.
- Maturity Date: The earlier of December 31, 2017, or the full conversion of the note.
- Conversion Terms: Convertible into common stock at 75% of the price per share paid by investors in a contemplated securities offering (Form S-1 File No. 333-217956).
- Lender Identity: Leonard Mazur, the Company's Executive Chairman, Secretary, and Director.
Material Changes
The primary material change is the execution of the new $1,000,000 Bridge Note. This follows a similar agreement executed on May 10, 2017, for $1,500,000 with the same lender. The filing notes a "most favored nation" clause: if the Company enters into third-party debt financing with better terms while this note is outstanding, the Lender may elect to amend the Bridge Note to incorporate those terms.
Guidance, Risks, and Contingencies
The filing does not provide specific financial guidance or outlook. The primary contingency is the Company's ability to complete the contemplated securities offering referenced in the conversion terms. If the offering does not occur or terms change, the conversion mechanism may be affected. The filing incorporates by reference the full terms of the agreement from a previous 10-Q filing.
Investor Verification Checklist
- Verify the status of the contemplated Form S-1 securities offering (File No. 333-217956) to understand the conversion price trigger.
- Review the total outstanding debt, including the $1,500,000 note from May 2017 and the $590,000 drawn from this new note.
- Assess the dilution impact of the 75% conversion discount on existing shareholders.
- Confirm the Company's liquidity position given the maturity date of December 31, 2017.